Ketamine Therapy in Oregon

Oregon has established a relatively progressive regulatory framework for ketamine therapy, operating within both federal and state-level guidelines. Ketamine remains a Schedule III controlled substance under the federal Controlled Substances Act, meaning it is legally available for medical use when administered or prescribed by a licensed provider. In Oregon, ketamine infusion clinics are permitted to operate under the supervision of licensed physicians, nurse practitioners, and other qualified medical professionals who hold the appropriate DEA registration to prescribe and administer controlled substances. Clinics must comply with Oregon Medical Board regulations, maintain proper documentation of patient evaluations, and adhere to standards of care that prioritize patient safety throughout the treatment process.

Oregon is also notably one of the first states in the nation to establish a regulated framework for psilocybin-assisted therapy through Measure 109, which passed in 2020. While this does not directly govern ketamine, it reflects Oregon's broader openness to exploring psychedelic and dissociative therapies within a structured, supervised medical context. Ketamine clinics in Oregon are distinct from psilocybin service centers and operate under separate medical licensing requirements. Providers offering ketamine for off-label uses, such as treatment-resistant depression, PTSD, and anxiety, must ensure that patients receive thorough psychiatric and medical evaluations prior to beginning treatment.

Patients seeking ketamine therapy in Oregon should be aware of the following general regulatory considerations:

• Treatment must be administered or directly supervised by a licensed medical professional with a valid DEA registration
• Clinics are subject to inspection and oversight by the Oregon Medical Board and the Oregon State Pharmacy Board
• Ketamine infusions are generally not covered by insurance when used off-label, making out-of-pocket costs a common reality for patients
• Informed consent documenting the off-label nature of treatment is typically required before therapy begins
• Compounded ketamine products, including oral troches and nasal sprays, must be sourced from licensed compounding pharmacies compliant with Oregon and federal pharmacy law

As the evidence base for ketamine therapy continues to grow, Oregon's regulatory environment is expected to evolve accordingly. Prospective patients and providers are encouraged to consult the Oregon Medical Board and stay current with guidance from the Drug Enforcement Administration (DEA) regarding any updates to prescribing and telemedicine rules, particularly following recent federal reassessments of remote ketamine prescribing practices. Choosing a clinic that operates transparently within these established legal and clinical frameworks is an important step in ensuring a safe and effective treatment experience.